716 related articles for article (PubMed ID: 23246165)
1. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
4. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS).
Drexel H; Chazelle F; Fauer C; Lautsch D; Gitt AK
Wien Klin Wochenschr; 2011 Oct; 123(19-20):611-7. PubMed ID: 21947362
[TBL] [Abstract][Full Text] [Related]
5. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
6. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).
da Silva PM; Cardoso SM;
Rev Port Cardiol; 2011 Jan; 30(1):47-63. PubMed ID: 21425743
[TBL] [Abstract][Full Text] [Related]
7. The lipid triad, or how to reduce residual cardiovascular risk?
Girard-Mauduit S
Ann Endocrinol (Paris); 2010 Mar; 71(2):89-94. PubMed ID: 20303470
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): results of the Dyslipidemia International Study (DYSIS).
Viigimaa M; Erglis A; Latkovskis G; Mäeots E; Petrulionienė Ž; Šlapikas R; Gocentiene A; Bramlage P; Brudi P
Medicina (Kaunas); 2014; 50(1):44-53. PubMed ID: 25060204
[TBL] [Abstract][Full Text] [Related]
9. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
11. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.
Ambegaonkar BM; Bash LD; Chirovsky DR; Jameson K; Grant S; Nocea G; Pettersson B; Sazonov V
Eur J Intern Med; 2013 Oct; 24(7):656-63. PubMed ID: 23953848
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
[TBL] [Abstract][Full Text] [Related]
14. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
15. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
17. Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS).
Marques da Silva P; Massano Cardoso S; Ferreira AM;
Prim Care Diabetes; 2015 Aug; 9(4):283-9. PubMed ID: 25449144
[TBL] [Abstract][Full Text] [Related]
18. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).
Raal FJ; Blom DJ; Naidoo S; Bramlage P; Brudi P
Cardiovasc J Afr; 2013 Sep; 24(8):330-8. PubMed ID: 24240385
[TBL] [Abstract][Full Text] [Related]
20. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China).
Zheng W; Zhang YJ; Bu XT; Guo XZ; Hu DY; Li ZQ; Sun J
Medicine (Baltimore); 2017 Nov; 96(46):e8555. PubMed ID: 29145263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
